- Supplementary Figure 1. pMerlin and Merlin levels in patient's fibroblasts. NPE stands for Normalized Protein Expression; Bars represent the SD from t[supplements/216614_file08.pdf]
- Supplemental Data 1[supplements/216614_file09.pdf]
- Supplementary Figure 3. PCA-biplot of phenotypical NF2 data by NF2-mutation groups. VS: Vestibular Schwannoma; Age Dx: Age at diagnosis; PS: Periphera[supplements/216614_file10.pdf]
- Supplementary Figure 4. Sanger sequencing comparison between blood and fibroblast samples of a NF2 patient.[supplements/216614_file11.pdf]
- Supplementary Table 1. NF2 Patients summary.[supplements/216614_file12.docx]
- Supplementary Table 2. Major interventions in relation to Genetic Severity Score.[supplements/216614_file13.pdf]
- Supplementary Table 3. NF2 Phenotype quantification.[supplements/216614_file14.pdf]
- Supplementary Table 4. Revising pathogenicity associated to NF2 mutations according to GSS. Patients with an unexpected phenotype according to GSS are[supplements/216614_file15.pdf]
- Supplementary Table 5. Demographic data according to Functional Genetic Severity Score.[supplements/216614_file16.pdf]
- Supplementary Table 6. Tumor burden, presence of ocular features and hearing outcome according to Functional Genetic Severity Score[supplements/216614_file17.pdf]
- Supplementary Table 7. Major interventions in relation to Functional Genetic Severity Score.[supplements/216614_file18.pdf]
- Supplementary Table 8. Intragroup Variability of Merlin, pERK, age at diagnosis and age at hearing loss.[supplements/216614_file19.pdf]
- Supplementary Table 9. A) FGSS and NF2 disease-causing variant regression model. B) FGSS and NF2 disease-causing variant regression model.[supplements/216614_file20.pdf]
- Supplementary Materials and Methods[supplements/216614_file21.docx]